The Hippo Pathway and YAP/TAZ–TEAD Protein–Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment
Citations Over TimeTop 10% of 2015 papers
Abstract
The Hippo pathway is an important organ size control signaling network and the major regulatory mechanism of cell-contact inhibition. Yes associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) are its targets and terminal effectors: inhibition of the pathway promotes YAP/TAZ translocation to the nucleus, where they interact with transcriptional enhancer associate domain (TEAD) transcription factors and coactivate the expression of target genes, promoting cell proliferation. Defects in the pathway can result in overgrowth phenotypes due to deregulation of stem-cell proliferation and apoptosis; members of the pathway are directly involved in cancer development. The pharmacological regulation of the pathway might be useful in cancer prevention, treatment, and regenerative medicine applications; currently, a few compounds can selectively modulate the pathway. In this review, we present an overview of the Hippo pathway, the sequence and structural analysis of YAP/TAZ, the known pharmacological modulators of the pathway, especially those targeting YAP/TAZ-TEAD interaction.
Related Papers
- → A Combined Experimental and Computational Strategy to Define Protein Interaction Networks for Peptide Recognition Modules(2002)713 cited
- → Protein–protein interactions: from global to local analyses(2008)28 cited
- → The Hippo–YAP pathway in organ size control and tumorigenesis: an updated version(2010)1,133 cited
- → Detection of Peptides, Proteins, and Drugs That Selectively Interact With Protein Targets(2002)38 cited
- → Abstract IA04: Regulation of the Hippo pathway in cancer(2020)